<figure><img src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221110111156/636cd8cf9c7e80680e092e62jpeg.jpg" alt="" width="4096" height="2731"/><figcaption>A health worker in Jumla administers Covidshield AstraZeneca vaccine to an elderly this week. Photo: LAXMI NGAKHUSI/UNICEF NEPAL</figcaption></figure>Over 1.6 million Nepalis have so far been inoculated against the coronavirus, all of them with the AstraZeneca vaccine that several <a href="http://‘The damage is done’: Europe’s caution over AstraZeneca vaccine could have far-reaching consequences" target="_blank" rel="noopener noreferrer">European countries have suspended</a> because of fears of blood clots.With a turnout of 65% of frontline workers, vulnerable groups and people over the age of 65, Nepal has completed the <a href="https://www.nepalitimes.com/banner/nepal-fights-infodemic-to-push-vaccine/" target="_blank" rel="noopener noreferrer">second phase of its Covid-19 vaccination</a> rollout with the Covishield vaccine either donated or bought from the Serum Insitute of India.“We have managed to protect the groups most vulnerable to Covid-19 from the possible second wave,” Shyam Raj Upreti, head of the Government Covid Vaccine Strategy told Nepali Times. “The fact that there have been no serious side effects has increased the acceptance level of the vaccine among the masses and health practitioners themselves.”Read also: <a href="https://www.nepalitimes.com/editorial/its-not-over-yet/" target="_blank" rel="noopener noreferrer">It's not over yet</a>, EditorialHowever, reports of some EU nations, Thailand and other countries suspending the use of the AstraZeneca Oxford vaccine because of serious blood clots among some recipients may result in <a href="https://www.nepalitimes.com/banner/why-is-there-vaccine-hesitancy-in-nepal/" target="_blank" rel="noopener noreferrer">vaccine hesitancy</a> among the remaining population. Covishield is the brand name of the Indian-made version of AstraZeneca.Germany, France, Italy and Spain suspended the vaccine program , following in the footsteps of by Ireland, the Netherlands, Denmark, Norway, Sweden and Latvia discontinuing the vaccine earlier this week. Austria has temporarily paused the use of certain batches. Thailand is the first country in Asian nation to halt AstraZeneca shots.The <a href="https://edition.cnn.com/2021/03/16/europe/who-astrazeneca-europe-coronavirus-tuesday-intl/index.html" target="_blank" rel="noopener noreferrer">suspensions have baffled public health experts</a> who warn that there is neither enough data to justify the decision, nor evidence to blame the blood clots on the vaccine. It is especially worrisome because some European countries suffering their third wave of Covid-19 desperately need the vaccines.“To date, the vaccine has been safe in this part of the world, so its benefits far outweigh the risk,” said epidemiologist Lhamo Yangchen Sherpa, while cautioning that serious side effects should be monitored and their underlying causes studied.The suspensions in Europe, however, may be a blessing in disguise for countries like Nepal which have faced delays in shipments of AstraZeneca from India because of the rise in global demand. The price of the 2.2 million doses that Nepal had ordered from the Serum Institute also went up to $5 because of the shortage. It bought the first lot for $4 per dose.Nepal has approved two coronavirus vaccines for emergency use, Covishield AstraZeneca and China’s Sinopharm. So far, the government has only administered Covidshield and Nepali experts see no reason to discontinue the vaccine without a real causal link between AstraZeneca and the blood clots.With only about 600,000 doses in stock, Nepal needs to procure another 1.5 million shots if it wants to provide second doses starting from 20 April for those who inoculated in the first and second phases. Vaccine availability will also determine when the third phase aimed at people in the age group 55-64 age group will begin.“There is every likelihood that politics is involved in this decision to suspend AstraZeneca in the EU. We know that this vaccine is very safe, but it protects us from Covid and its more serious symptoms,” says Buddha Basnyat of the Patan Academy of Medical Sciences.Nepal has yet to receive another 1 million doses of Covidshield it ordered last month. Serum Institute of India was unable to deliver it on 15 March as expected. Similarly, Nepal received only 348,000 doses of Covishield vaccine under the COVAX initiative on 7 March of the promised 2.2 million doses. The next batch was not expected before May, but it could now be shipped earlier because of the suspensions.China, on the other hand, has increased its gift of Sinopharm vaccines to Nepal from 500,000 to 800,000 but there is a delay in procurement with Beijing insisting that Nepal send a plane to collect it .The shortfall in supply and procurement challenges have forced the Health Ministry to allow private companies to import other vaccines, including the Covaxin manufactured by Bharat Biotech in India.The <a href="https://www.nepalitimes.com/latest/nepal-braces-for-new-wave-with-vaccine-drive/" target="_blank" rel="noopener noreferrer">vaccination drive</a> and fewer daily positive cases have given Nepalis a false sense of security. Youth are out and about, shopping malls, cinema halls and dance bars are crowded, schools and offices have stopped maintaining physical distance.At a time when neighbouring <a href="https://www.nepalitimes.com/editorial/its-not-over-yet/" target="_blank" rel="noopener noreferrer">India is experiencing a possible second wave</a>, public health experts say the public has to be even more vigilant and follow safety precautions. Even those who have been vaccinated must remember that they can still be a carrier.Lhamo Yangchen Sherpa’s advice is: “The pandemic is not over, we can’t let our guard down. Vaccinate if possible, increase testing and continue to mask up, wash hands and maintain distance.”

original

674x448

610x380

500x500

400x266

400x240

400x203

301x200

1250x600

1084x550

Despite doubts, Nepal sticks with AstraZeneca jabs

<figure><img src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181124/636be2bb9c7e80680e083ec6jpeg.jpg" alt="" width="1656" height="750"/><figcaption>Vaccine trial of a Covid-19 vaccine at Oxford University’s Jenner Institute. Photo: UNIVERSITY OF OXFORD/JOHN CAIRNS</figcaption></figure>Many Nepalis who had felt their government had not done enough <a href="https://www.nepalitimes.com/here-now/when-will-nepals-covid-vaccine-turn-come/" target="_blank" rel="noopener noreferrer">‘vaccine diplomacy’</a> to for Covid-19 immunisation could have been assured by visiting Indian Foreign Secretary Harsh Vardhan Shringla’s remarks on Thursday that India would give preference to Nepal when trials are over.Indeed, it may be more practical and cheaper for Nepal to rely on vaccine supplies from research centres in India and China than multinationals, whose supplies of new vaccines are ‘booked’ by the world’s richest countries into next year.Handing over 2,000 vials of the broad-spectrum antiviral drug, Remdesivir, to Foreign Minister Pradeep Gyawali, Shringla said: "We will make the vaccine accessible and affordable, and it goes without saying that first priority will be for our closest neighbours like Nepal. We will put our health ministers and regulators in touch when this vaccine enters the market, Nepal will have the fullest benefit."<figure><img src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181124/636be2be9c7e80680e083ec7jpeg.jpg" alt="" width="1920" height="1080"><figcaption> </figcaption></figure>This week, the vaccine made by Oxford University in collaboration with the British-Swedish firm AstraZeneca was said to have 60-90% efficacy against Covid-19. The Oxford Vaccine has relevance for Nepal because the <a href="https://www.seruminstitute.com/" target="_blank" rel="noopener noreferrer">Serum Institute of India had</a> started manufacturing millions of doses of this vaccine long before the preliminary results of the trial came in.The Serum Institute of India is the world’s largest vaccine producer and already well-known in Nepal, especially for its anti-rabies vaccine that is commonly used here. The company had so much faith in the Oxford Vaccine, and it felt there would be such a rush later on, that it just went ahead and started manufacturing the vaccine, glass vials and stainless steel vats.Sure enough, preliminary results of the Oxford Vaccine now show that this gambit may have paid off for all concerned, including the people in India and its neighbouring countries.Adar Poonawallah, CEO of the Serum Institute of India has clearly made it his mission to manufacture the Covid-19 vaccine for the world’s poor. None other than Bill Gates is so impressed with his dedication that his foundation has committed millions of dollars to help with the project.Even as global Big Pharma roll out new vaccines, the difficult part will be to find ways to pay for the poorest people in the world’s poor countries to be immunised against Covid-19. Collaborative efforts like the one by the Serum Institute of India and COVAX appear to be the way to go.There is another interesting connection between the Oxford Vaccine and Nepal. The Chief Investigator of the Oxford Vaccine study, Prof Andrew Pollard has a long history of working in Nepal, especially in the prevention of typhoid fever. In December 2019, a paper on the milestone typhoid conjugate vaccine trial was published in <a href="http://www.nejm.org/doi/full/10.1056/NEJMoa1905047" target="_blank" rel="noopener noreferrer">The New England Journal of Medicine</a> by doctors at Patan Hospital in collaboration with Pollard and colleagues. This breakthrough may well lead to policy changes around the world where typhoid is still rampant.The unusual thing about the Oxford Vaccine is that, for some reason, the scientists administered only a half-dose of the vaccine on one group followed by the full second dose, as opposed to administering two full doses. Amazingly, the group that got the half dose followed by the full dose had a 90% vaccine efficacy compared to the group that was administered the full two doses, which registered only a 60% efficacy.It will be intriguing to see if the half dosage was planned, or was an oversight that leads to this welcome finding. The history of medical breakthroughs abounds in such serendipitous discoveries.The Oxford Vaccine announcement was preceded by American companies Pfizer and Moderna unveiling the breathtaking efficacy (&gt;90%) of their own Covid-19 vaccines. However, besides the $60 cost per dose, the cold chain maintenance of -70oC for Pfizer’s vaccine would be impossible for countries like Nepal.The Oxford Vaccine, on the other hand, does not require such extreme cold chain maintenance. The regular vaccine cold chain 2-8oC will suffice. More importantly, the cost is thought to be substantially less.<img src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181124/636be2c19c7e80680e083ec8jpeg.jpg" alt="" width="1214" height="690"><img src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181124/636be2c49c7e80680e083ec9jpeg.jpg" alt="" width="1188" height="754">It is clear that <a href="https://www.nepalitimes.com/opinion/a-covid-19-exit-strategy-for-nepal/" target="_blank" rel="noopener noreferrer">for Nepal, just the discovery of an efficacious vaccine will not be enough</a>. We must be able to have access to it, and also afford it. In addition, whether the vaccine prevents transmission or not is also going to be important -- together with whether or not it prevents severe illness.Their important considerations are all pending, but for now, we need to continue to wear masks, wash hands, and maintain social distancing. We may have to continue that practice even after the vaccination campaigns start.Because the Oxford Vaccine will be distributed by governments (not Oxford University) the Nepal government will need to liaise with the <a href="https://www.who.int/initiatives/act-accelerator/covax" target="_blank" rel="noopener noreferrer">World Health Organization-initiated COVAX</a>, which is the only global inter-governmental initiative working with manufacturers to ensure Covid-19 vaccines are available worldwide to both the rich and the poor.Most industrialised countries have already started placing orders for vaccines from Pfizer, Moderna and AstraZeneca, so there is every likelihood that COVAX will concentrate on ensuring vaccine supply to less-developed countries.Along with the Indian vaccines, results of the Chinese vaccine against Covid-19, which may well be just as effective and affordable, will probably be announced soon.The <a href="https://www.nepalitimes.com/latest/vax-populi/" target="_blank" rel="noopener noreferrer">Nepal government needs to coordinate closely</a> with groups like COVAX and keep its attention focused on obtaining the vaccine for Nepalis of all socio-economic strata.With Harsh Vardhan Shringla’s assurance this week in Kathmandu, it may also be useful to connect directly with the Serum Institute of India, which can play an instrumental role in supplying this all-important vaccine against Covid-19.<a href="https://www.nepalitimes.com/opinion/what-is-novel-about-the-novel-coronavirus/" target="_blank" rel="noopener noreferrer">Buddha Basnyat</a> is a clinical researcher at Patan Academy of Health Sciences and contributes this <a href="https://www.nepalitimes.com/opinion/what-is-novel-about-the-novel-coronavirus/" target="_blank" rel="noopener noreferrer">health column</a>, Dhanvantari, for Nepali Times.

Buddha Basnyat

Glimmers of hope for Nepal on vaccine

<figure><img width="2048" height="1282" src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181120/636be1af9c7e80680e083e61jpeg.jpg" alt=""/><figcaption>Photo: MONIKA DEUPALA</figcaption></figure>With the <a href="https://www.nepalitimes.com/latest/double-whammy-air-pollution-and-covid-19/">pre-winter resurgence of Covid-19</a> around the world and in Nepal, pressure is mounting on governments to procure vaccines to protect their populations.
Last week, the <a href="https://www.nepalitimes.com/latest/vax-populi/" target="_blank" rel="noopener noreferrer">Nepal government set up a committee</a> of secretaries of the Finance, Home, Health and Foreign Affairs ministries to study vaccines under development as well as procedures to procure them. But Nepal is far behind other countries, which have already ‘booked’ their future supplies.
On Wednesday President Bidya Devi Bhandari signed an ordinance empowering the government to import Covid-19 vaccines from international pharmaceutical companies, and to use them even if they are authorised only for emergency use.
<a style="font-size: 15px; letter-spacing: 0.01em;" href="https://www.nepalitimes.com/latest/vax-populi/" target="_blank" rel="noopener noreferrer">VAX POPULI</a>, Sonia Awale
However, there is no effective strategy to ensure vaccines for all as distribution in Nepal comes with the challenge of taking it to poor and remote corners of the country. Experts fear that even when the vaccines become available, the campaign will be plagued by the same socio-economic inequities that afflict the medical sector.
“We need to immediately start identifying vulnerable groups like <a href="https://www.nepalitimes.com/here-now/nepal-health-workers-battle-covid-19-but-also-stigma/" target="_blank" rel="noopener noreferrer">frontline health workers</a>, <a href="https://www.nepalitimes.com/here-now/spared-at-first-elderly-hit-hard-by-covid-19/" target="_blank" rel="noopener noreferrer">the elderly</a> or those with comorbidities to prioritise for immunisation,” says Bikash Gauchan, a physician at Bayalpata Hospital in the under-served western district of Achham.
“We also need to set up proper cold chain facilities across the country as soon as possible and have a well thought out distribution plan so that when the vaccine does arrive, we can hit the ground running,” he adds.
The silver lining is that Nepal already has a successful <a href="https://www.nepalitimes.com/banner/polio-hunt/" target="_blank" rel="noopener noreferrer">childhood immunisation</a> network that has successfully mobilised <a href="https://www.nepalitimes.com/latest/enlisting-female-health-volunteers-to-fight-covid-19/" target="_blank" rel="noopener noreferrer">Female Community Health Volunteers</a>, and they can deliver vaccines to the homes of the elderly who cannot make it to clinics. Monitoring the follow-up second dose for some of the vaccines will be crucial, although Nepal’s health system has experience with maintaining a cold chain for other campaigns.
<a href="https://www.nepalitimes.com/latest/nepali-diaspora-hit-by-covid-surge/">Nepali diaspora hit by Covid surge</a>, Nepali Times
Despite recent breakthroughs in trials (see box) public health experts stress the importance of exploring vaccine supply options closer to home. As of now, 11 vaccines developed in several parts of the world are in the third phase of <a href="https://www.nepalitimes.com/opinion/countries-cooperating-to-find-covid-19-cure/" target="_blank" rel="noopener noreferrer">clinical trials</a> with many of them expected to be as effective.
Neighbouring China and India are at the forefront. And Nepal should have begun its ‘vaccine diplomacy’ much before this to secure its supply of shots.
There is also the uncertainty of vaccine efficacy depending on the strain: the same vaccine could be highly effective against people in the West but not as much in South Asia where people suffer from chronic malnutrition and multiple infections.
“For a working vaccine to be made within a year is an amazing victory for science but we also need to know that these vaccines are designed for their population. So I’d want to know more about the vaccines in India and China,” says Sameer Mani Dixit of the Centre for Molecular Dynamics Nepal. “Particularly China, as it was where the pandemic started but <a href="https://www.nepalitimes.com/latest/what-nepal-can-learn-from-china-about-covid-19/" target="_blank" rel="noopener noreferrer">has since controlled it effectively</a> unlike rest of the world.”
<a href="https://www.nepalitimes.com/opinion/the-truth-about-the-chloroquine-scam/" target="_blank" style="font-size: 15px; letter-spacing: 0.01em;" rel="noopener noreferrer">Buddha Basnyat</a> of the Patan Academy of Health Sciences agrees. He says: “China looks at the reality in our backyard. So a more suitable vaccine for us could come from the Chinese, particularly because they have a track record of having developed better vaccine for this part of the world.”
Indeed, the JEVAX made by the researchers in Chengdu is now the most widely used jab against Japanese Encephalitis because it’s more cost effective compared to its western vaccines.
Nepal Health Research Council is once again considering conducting Phase III clinical trial of Coronavac by China’s Sinovac Biotech after an initial divided opinion over its safety. The vaccine has shown quick immune response in mid-stage trials in South America and parts of Asia.
In India, The Serum Institute has anticipated demand by already manufacturing 40 million doses of AstraZeneca’s potential Covid-19 vaccine. It will also soon manufacture Novavax.
Similarly, researchers at the Indian Institute of Science have designed a protein-based heat-tolerant vaccine that can stay stable for a month at 37°C, and could endure temperatures as high as 100°C if freeze dried, a feature that could be a game changer for mass vaccination campaigns in lower and middle income countries in Asia and Africa.
The other factor to consider will be the duration of the immunity after each vaccine shot, as well reinfection groups and if antibodies developed in the first episode helps fight the mutated forms of the virus.
With Covid-19 crisis continuing to spread rapidly across Nepal and at 10 fatalities per million population (same as Pakistan and much higher than China’s 3), it is not too early to start dialogue with Gavi, the vaccine alliance, COVAX and agencies like the World Bank and World Health Organisation to help procure the most cost effective approach to vaccines most suitable to Nepal’s conditions.
Alternatively, many pharmaceutical companies will want to play the field in order to boost their profile. In fact, embassies and foreign donors are already hard at work pushing for trails and deals.
“There is bound to be vaccine politics and it will mostly likely be ugly,” predicts Sher Bahadur Pun of the Health Ministry. “But we should not lose track of two things: efficacy of the vaccine against our population and its economic viability. If we do that we should be on the right path, more or less.”
In all this excitement, Nepal’s health authorities must also keep an eye on the plight of infected people and many more to come as <a href="https://www.nepalitimes.com/opinion/prevention-while-searching-for-a-cure/" target="_blank" rel="noopener noreferrer">they wait for a vaccine</a>. The results of current treatment regimens ranging from plasma therapy to administering Remdesivir have been patchy. And as scientists study the long-term impact of Covid-19 on patients even after they recover, making an optimal use of resources becomes even more significant.
So far, the government has been faulted for squandering months of lockdown, not carrying out sufficient tests and contact tracing, not increasing hospital capacity and equipment, and letting the people fend for themselves.  
The result is that Nepal is <a href="https://www.nepalitimes.com/banner/heat-map-of-nepals-covid-19-hotspots/" target="_blank" rel="noopener noreferrer">suffering a sustained surge</a>, with more than 1,400 new cases a day, over 60% of them in Kathmandu Valley alone and a quarter of those tested coming out positive. There is also a surge in symptomatic patients, even among those without pre-existing conditions, and those sick enough to require ICU and ventilator.
Even when the government does act, the <a href="https://www.nepalitimes.com/latest/coronavirus-coordination-committee-doesnt-coordinate/" target="_blank" rel="noopener noreferrer">priorities seem to be misplaced</a>. For instance, health experts say the emphasis in the past months should have been on high flow oxygen therapy or High Dependency Units rather than Intensive Care Units in hospitals.
“It would have been cheaper, it does not require highly trained staff or sophisticated equipment, and it would have freed up the ICUs for the really critical patients,” adds Pun, who himself is at the Health Ministry, and this possibly means his advice is not being taken.
Insiders say it will likely take upwards of six months for the first vaccines to arrive in Nepal, and there will be a rush by the rich, the powerful and those with political connections to get their shots. The marginalised, poor, those in remote areas will be the last to get their injections, unless the government has fair and effective rules in place and implements them.
Till then, there is little else to do than <a href="https://www.nepalitimes.com/opinion/silver-linings-in-the-covid-cloud/" target="_blank" rel="noopener noreferrer">keep masking up this winter, avoid large gatherings, keep distance and wash hands regularly</a>.
Says <a href="https://www.nepalitimes.com/opinion/a-covid-19-exit-strategy-for-nepal/" target="_blank" rel="noopener noreferrer">Buddha Basnyat</a>: “The mask is the best vaccine we have at the moment. These safety measures have largely reduced hospitalisation due to other infections in 2020, masks in particular will also protect us from winter pollution in the coming months.”<h2>The Vaccine Race</h2>The global resurgence of Covid-19 in the northern winter has coincided with breaking news every day of successful new vaccine trials.First the Russians announced a vaccine in September that is 92% potent against SARS-CoV-2.  Last week Pfizer unveiled a 90% effective vaccine, which on Wednesday was upgraded to 95% efficacy without side effects. Moderna was next with an efficacy of 95%, and not needing extreme refrigeration. More companies in China, India and Europe are conducting their own trials.Public health experts have hailed the developments, but warn that vaccines will not be universally available till late 2021 and even so will not provide full protection. They suggest continuing with masking up, keeping distance and avoiding crowded indoor places.Pfizer and its German partner BioNTech’s mRNA-based vaccine came out declaring over 90% effectiveness but only at -70°C ultra cold chain which will be a challenge even for countries with the best health facilities in the world.Massachusetts-based Moderna’s RNA shot has 94.5% efficacy, seems to also prevent severe infections and remains stable in medical and home refrigerators for up to 30 days, in freezers (-20°C) for up to six months, and at room temperature for up to 12 hours.Even so, poorer countries are unlikely to get coronavirus vaccine any time soon. Even the biggest pharmaceutical multinationals can only manufacture a limited quantity of the vaccine over the next year.Pfizer has capped its production at 1.4 billion for 2021, 80% of which has already been booked through advance purchase agreement by the US, UK, EU, Canada and Japan. Moderna expects to manufacture 20 million doses this year and up to one billion in 2021.On the other hand, <a href="https://www.nepalitimes.com/latest/sputnik-v-vaccine-mystery-in-nepal/" target="_blank" rel="noopener noreferrer">Russian’s Sputnik V</a> has been overshadowed by new developments, and due to lack of sufficient data to back up its claim of 92% efficacy. Although geopolitical rivalry with the West has given it negative publicity, some health agencies have not ruled it out.

Sonia Awale

When will Nepal’s Covid vaccine turn come?

<figure><img width="640" height="311" src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109181120/636be1b29c7e80680e083e62jpeg.jpg" alt=""/><figcaption>Nepal Army special funeral team brings home the first fatality from Covid-19 in Bhojpur District. She was a 24-year-old woman. The government's challenge is to bring the Covid-19 vaccine to remote parts of Nepal like these. Photo: RSS</figcaption></figure>Nepal’s <a href="https://www.nepalitimes.com/banner/heat-map-of-nepals-covid-19-hotspots/" target="_blank" rel="noopener noreferrer">surge of Covid-19 continues unabate</a>d  with new hotspots, and because of inadequate testing, no one really knows how much and how fast the pandemic has spread.The government has left Nepalis to their own devices, only issuing guidelines on precautions, but stopping free testing and treatment. Meanwhile the daily positivity rate and fatalities have not come down. As of Thursday, out of the 9,805 people tested nationwide 2,103 were positive, which gives a very high positivity rate of 21.4%.<a style="font-size: 15px; letter-spacing: 0.01em;" href="https://www.nepalitimes.com/here-now/when-will-nepals-covid-vaccine-turn-come/" target="_blank" rel="noopener noreferrer">When will Nepal's Covid vaccine turn come?</a>, Sonia Awale Nepal’s death rate from the coronavirus of 43 per million is much lower than India (93%), but much higher than China and Sri Lanka (3%). This points to poor prevention measures as well as inadequate or unaffordable hospital treatment. The only option for Nepal is to <a href="https://www.nepalitimes.com/here-now/when-will-nepals-covid-vaccine-turn-come/" target="_blank" rel="noopener noreferrer">wait for vaccines to be available</a>, but even on this it has moved too late. Many governments around the world have pre-booked vaccines from pharmaceutical companies like Pfizer and Moderna, and most countries will first prioritise their own citizens.Last week, the Nepal government finally set up a committee of secretaries of the Finance, Home, Health and Foreign Affairs ministries to study vaccines under development as well as procedures to procure them.On Wednesday President Bidya Devi Bhandari signed an ordinance empowering the government to import Covid-19 vaccines from international pharmaceutical companies, and to use them even if they are authorised only for emergency use.Despite this, Nepal will possibly be one of the last countries in the world to get a vaccine, and even when the first vials arrive perhaps by the middle of 2021, the poorest Nepalis living in the remotest areas will be the last in line to get them.The government, which has <a href="https://www.google.com/url?client=internal-element-cse&amp;cx=bead8272edd0f2143&amp;q=https://www.nepalitimes.com/here-now/kcs-fast-highlights-nepals-covid-19-failure/&amp;sa=U&amp;ved=2ahUKEwiSi7fx3pDtAhWlwjgGHWzzCnwQFjAAegQIBBAC&amp;usg=AOvVaw18PYxlijebm6Z8s6c8PcRX" target="_blank" rel="noopener noreferrer">failed all these years to make free health care accessible to all</a>, will have to prove that its vaccine distribution is fair, and the poor in remote areas of the country are not left out. Says Bikash Gauchan, a physician stationed in remote Achham district: “We need to immediately start identifying vulnerable groups like frontline health workers, the elderly or those with co-morbidities to prioritise for immunisation, and to have an effective distribution plan for remote areas.”Nepal is internationally recognised as a model low-income country with an effective vaccination programs against measles, <a href="https://www.nepalitimes.com/banner/polio-hunt/" target="_blank" rel="noopener noreferrer">polio</a> and other childhood killer diseases. It has valuable experience in deploying a nationwide network of <a href="https://www.google.com/url?client=internal-element-cse&amp;cx=bead8272edd0f2143&amp;q=https://www.nepalitimes.com/latest/enlisting-female-health-volunteers-to-fight-covid-19/&amp;sa=U&amp;ved=2ahUKEwjaqeaY35DtAhUSyzgGHYXhBtoQFjAAegQIAxAC&amp;usg=AOvVaw1_j5Qa_kWIBHLL5EZjqV1b" target="_blank" rel="noopener noreferrer">Female Community Health Volunteers</a>, and Nepal’s Covid-19 vaccine delivery will have to re-learn from its own best practices.Monitoring the follow-up vaccine dose can gain from Nepal’s acclaimed <a href="https://www.google.com/url?client=internal-element-cse&amp;cx=bead8272edd0f2143&amp;q=https://www.nepalitimes.com/banner/tb/&amp;sa=U&amp;ved=2ahUKEwjxlPay35DtAhWizDgGHd_SDB4QFjAFegQIBRAC&amp;usg=AOvVaw1d367zHYY84fBDOJyCB8HY" target="_blank" rel="noopener noreferrer">DOTS program</a> to deliver anti-tuberculosis therapies, and Nepal’s rural health care workers have experience in maintaining the cold chain from previous <a href="https://www.google.com/url?client=internal-element-cse&amp;cx=bead8272edd0f2143&amp;q=https://www.nepalitimes.com/banner/a-shot-in-the-arm-for-vaccines-in-nepal/&amp;sa=U&amp;ved=2ahUKEwj07oLT35DtAhW6yDgGHe6ZCsYQFjAAegQIABAC&amp;usg=AOvVaw2VfJkLuf5k3bEjPG4_59-X" target="_blank" rel="noopener noreferrer">vaccination programs</a>.  Despite recent breakthroughs in trials, public health experts say Nepal should be looking at neighbouring China and India and belatedly begin ‘vaccine diplomacy’ to secure its supply.Nepal Health Research Council is once again considering conducting Phase III clinical trial of Coronavac by China’s Sinovac Biotech after an initial divided opinion over its safety. The vaccine has shown quick immune response in mid-stage trials in South America and parts of Asia.In India, the Serum Institute has anticipated demand by already manufacturing 40 million doses of AstraZeneca’s potential Covid-19 vaccine. It will also soon manufacture Novavax.“There is bound to be vaccine politics and it will mostly likely be ugly,” predicts Sher Bahadur Pun of the Health Ministry. “But we should not lose track of two things: efficacy of the vaccine against our population and its economic viability. If we do that we should be on the right path, more or less.”

VAX POPULI

<figure><img width="800" height="534" src="https://superdesk-pro-c.s3.amazonaws.com/sd-nepalitimes/20221109151116/636bb6a99c7e80680e07bc76jpeg.jpg" alt=""/><figcaption></figcaption></figure>On Tuesday news broke about an agreement between the Russian Direct Investment Fund (RDIF) and Nepal’s Trinity Pharmaceuticals to import 25 million vials of the Sputnik V vaccines against Covid-19. But the deal is shrouded in mystery because the country’s Ministry of Health had no idea about the deal.
At a first glance it could be good news at a time when Nepal is reeling under the pandemic. But it seems no one in the government is aware of the deal. But the fact that announcement of such a massive deal did not come from the government, and doubts about whether the vaccine is safe has raised eyebrows.
What is more, Trinity Pharmaceuticals is not even registered as an importer under Nepal’s Department of Drug Management list of companies.
In a <a href="https://rdif.ru/Eng_fullNews/5852/">statement released on 29 September</a>, RDIF Chief Executive Officer Kirill Dmitriev said that about 90% of Nepalis will be provided with Sputnik V vaccine safely and effectively though clinics in the country.
“Unlike experimental vaccines based on monkey adenovirus or mRNA, Sputnik V vaccine was created on human adenoviral vectors platform, which has been studied over decades and has proven no negative effects in the long-term,” added Dmitriev. “We see a strong interest from other partners in Asia. RDIF is ready to supply Sputnik V vaccine to the countries of the region.”
In the same press release, the director of Trinity Pharmaceuticals in Kathmandu Kishor Adhikari is quoted as saying, ‘Trinity is waiting for results of the final trial of Sputnik V. As soon as the vaccine is approved by Government of Nepal we will make it available for the population of Nepal.’
Nepal saw a total of 1,559 new Covid-19 cases on Wednesday with 902 in Kathmandu Valley alone. With 1,057 people were discharged in the last 24 hours, the recovery rate now stands at 72.5%. Total confirmed cases now stands at 77,817 with 491 fatalities.201 patients are in ICU and 31 in ventilator support.
The Sputnik-V (trade name of<a href="https://sputnikvaccine.com/"> Gam-COVID-Vac</a>) vaccine was developed by Russia's Gamalia National Research Institute of Epidemiology and Microbiology on 11 August and was later registered by the country's health ministry.
Despite having been tested only in 76 people in early-stage clinical trials that lasted two months (June-July), Sputnik V was quickly approved for distribution in Russia, drawing criticism from the international scientific community as a premature decision. It normally takes a year or more to test vaccine safety and efficacy.
Gam-COVID-Vac is administered in two doses and is expected to provide immunity from SARS-CoV-2 for up to two years. The vaccine is based on the human adenovirus, a common cold virus and is fused with the spike protein of SARS-CoV-2 to stimulate an immune response.
So far, RDIF has announced supply agreements with Mexico (32 million doses), Brazil (up to 50 million doses and Uzbekistan (up to 35 million doses). India is importing another 100 million doses of the vaccine.
The results of the first and second rounds of clinical trials of the vaccine which were <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31866-3/fulltext">published in the Lancet Journal</a> on 4 September showed no serious adverse effects, but stable immune response in all participants, said the statement.
Post-registration phase III clinical trial involving 40,000 people is underway and the first results are expected to be published by October-November. Some mild side-effects have been reported in one of every seven people so far. This phase III trial is a crucial scientific step in order to prove vaccine safety and efficacy.
But back in Nepal, officials are unaware of the agreement. Before importing any new vaccine and drug, permission must be obtained from the Department of Drug Management.
Narayan Dhakal, director of the Department of Drug Management, says he had “no idea” about a Nepali company importing the vaccine against coronavirus from Russia.
The Chief Research Officer of the Nepal Health Research Council Meghnath Dhimal also told us he had no official information about a vaccine being imported from Russia.
Apart from Russia, Chinese pharmaceutical companies and Oxford University have also expressed their interest in conducting phase III <a href="https://www.nepalitimes.com/opinion/countries-cooperating-to-find-covid-19-cure/">clinical trials in Nepal</a>.
There are currently over 169 Covid-19 vaccines under development, with 26 in the human trial phase. The <a href="https://www.gavi.org/covax-facility">WHO has assured</a> that it will facilitate equitable access and distribution of a safe and effective vaccine in all countries with priority to people at most risk once it is found.

Sputnik V vaccine mystery in Nepal

mainNavigation

footerNavigation

opinionSubnav

coronavirus-vaccine

Despite doubts, Nepal sticks with AstraZeneca jabs

Glimmers of hope for Nepal on vaccine

When will Nepal’s Covid vaccine turn come?

VAX POPULI

Sputnik V vaccine mystery in Nepal